German SME supplying beam imaging and measurement instrumentation for particle accelerators in medical therapy and fundamental physics research.
VIALUX is a German SME from Chemnitz whose name describes their core business precisely: Messtechnik (measurement technology) + Bildverarbeitung (image processing). They design and supply precision optical measurement and digital imaging systems for demanding scientific environments, particularly particle accelerator facilities. In H2020, they contributed beam diagnostics and imaging instrumentation — first to the optimization of medical particle accelerators used in cancer treatment, then to fundamental physics experiments studying antimatter at low energies. Their value to large research consortia is as a specialist hardware and instrumentation provider that bridges the gap between physics requirements and deployable imaging solutions.
Contributed imaging and diagnostics expertise to both OMA (medical accelerators) and AVA (antimatter physics), reflecting a consistent core competency in visualizing and measuring particle beams.
In OMA (2016–2020), VIALUX contributed to Bragg peak detection, treatment planning support, and beam imaging for ion beam cancer therapy — directly applied medical physics instrumentation.
In AVA (2017–2021), they participated as a third party in antimatter research involving cooled and stored beams, ion traps, and precision spectroscopy — extending their instrumentation to pure physics environments.
The Bildverarbeitung (image processing) half of their business name is directly evidenced by their role across both projects, where imaging techniques and Monte Carlo simulation validation of beam images are central tasks.
VIALUX entered H2020 through OMA (2016–2020) with a clearly applied focus: imaging and diagnostics in service of cancer treatment — Bragg peak detection, beam quality monitoring, and treatment planning for ion beam therapy. Their second project, AVA (2017–2021), ran nearly in parallel but shifted the application domain entirely toward fundamental physics — antiproton/positron trapping, CPT symmetry tests, and precision spectroscopy of antimatter. This suggests VIALUX did not abandon medical physics but expanded laterally: their instrumentation proved general enough to serve accelerator physicists across both applied medical and pure-science contexts.
VIALUX is moving from applied medical physics toward serving fundamental physics consortia, positioning their imaging instrumentation as domain-agnostic across any particle accelerator environment — which widens their potential consortium value but keeps their profile firmly in large-scale physics infrastructure.
VIALUX has never led an H2020 project — they entered as a participant in OMA and as a third party (non-funded partner) in AVA, which is a deliberate specialist-supplier posture typical of instrumentation SMEs that attach to large training networks. Despite only two projects, they have accumulated 40 unique consortium partners across 12 countries, reflecting how MSCA-ITN consortia are structured: wide, multinational, and institution-heavy. Working with VIALUX means engaging a focused German technical supplier rather than a research institution — they deliver hardware and measurement capability, not scientific leadership.
With 40 unique partners across 12 countries from just two MSCA-ITN projects, VIALUX is embedded in wide European physics research networks centered on accelerator facilities. Their geographic reach is pan-European, with likely ties to CERN-adjacent institutions given the antimatter and particle therapy focus of both projects.
VIALUX occupies a narrow but durable niche: a German precision imaging SME that has successfully industrialized its measurement technology for deployment in cutting-edge particle physics research environments — both clinical (oncology accelerators) and fundamental (antimatter traps). Very few SMEs at this scale have credible participation records in both medical physics and fundamental physics consortia simultaneously, which gives them a rare cross-domain credential. For consortium builders, they represent a reliable specialist hardware contributor who can deliver compliant instrumentation without the overhead of a large research institute.
